Company profile
Evolutionary Genomics, Inc.
OTC: FNAM · Healthcare · Biotechnology
#1130 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
——FH —DQ 44GM —SS 24
v0.1 · 25/100 weight · pillars only
↑ listing tenure, filing timeliness · ↓ Piotroski F, workforce scale
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$1.9M
Employees
2
as of 2026-08-31
Market cap
$1.3k
as of 2026-08-31
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$12.5k$12.5k2020
Net income-$1.9M-$1.9M2022
Operating income-$2.0M-$2.0M2022
Total assets$2.4M$2.4M2022
Liabilities$3.9M$3.9M2022
Equity-$5.6M-$5.6M2022
Revenue trend
FY2015 – FY2020 · USD
FY15
FY15
FY16
FY17
FY18
FY19
FY20
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Evolutionary Genomics, Inc.’s revenue?
Evolutionary Genomics, Inc. booked $12.5k in FY2020 revenue, contracting 90% year over year — slower than 90% of Healthcare companies we track, at a -15479.7% net margin.
Peers · Healthcare
Cryomass Technologies Inc.——Relmada Therapeutics, Inc.38DThe Greater Cannabis Company, Inc.14DFirst Colombia Gold Corp.——Baseline Productions, Inc.——SYBLEU Inc——Neighbors
Douglas →Key facts
CEOSteven Bryan Warnecke
SectorHealthcare
IndustryBiotechnology
HeadquartersCastle Rock, CO
ExchangeOTC: FNAM
Employees2
IPO date2011-04-08
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.